Company intelligence / Profile preview

Nevro

Redwood City, California, United States

Ownership: Public · NVRO
Employees: ~900
Development stage: Commercial

Overview

Nevro’s proprietary high-frequency spinal cord stimulation therapy (“10 kHz Therapy”) has demonstrated significant long-term relief for chronic pain without paresthesia. The company’s devices are FDA-approved for multiple chronic pain indications including painful diabetic neuropathy and non-surgical back pain. Recent clinical results support improved outcomes with their AI-driven personalized therapy platform.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapyNeuromodulation device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Senza SCS System

Commercial

Indications: Chronic pain, Painful diabetic neuropathy, Failed back surgery syndrome

Financials

Market cap: $224.1M
Total revenue: $105.5M
Enterprise value: $182.7M

Beyond the preview

Go deeper on Nevro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nevro.

Explore the full profile